Entry into a Material Definitive Agreement. As previously disclosed, on July 22, 2023, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Development and Manufacturing Services Agreement (as amended by Amendment #1 thereto on July 24, 2023, the “Prior Agreement”) with ElevateBio Basecamp, Inc. (“ElevateBio”), pursuant to which ElevateBio has provided the Company with cell manufacturing, release and testing services for the Company’s lead product candidate, mivocabtagene auto…

Entry into a Material Definitive Agreement. As previously disclosed, on October 31, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Loan and Security Agreement (the “Loan and Security Agreement”) with Oxford Finance LLC, as collateral agent (the “Collateral Agent”), and certain lenders from time to time party thereto (the “Lenders”). The Loan and Security Agreement provides a non-dilutive term loan facility (the “Loan Facility”) of up to an aggregate principal amoun…

Chief Financial Officer — Gregory Martini: Appointment of Gregory Martini as Chief Financial Officer.

of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Director — Andrew Miller, Ph.D.: Dr. Andrew Miller was appointed as a Class III director and joined the Science and Technology Committee and Audit Committee.

Chief Technology Officer — Karen Walker: Karen Walker is retiring from her role as Chief Technology Officer.

Executive Chairperson of the Board — Christi Shaw: Christi Shaw was promoted to Executive Chairperson of the Board.

Results of Operations and Financial Condition. On January 12, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and outlining its strategic priorities for 2026, as well as announcing the appointment of Christi Shaw as Executive Chairperson of the Board of Directors of the Company (the “Board”) and providing certain preliminary financial information for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1…

Entry into a Material Definitive Agreement. On December 17, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Leerink Partners LLC and Morgan Stanley & Co. LLC as the representatives (the “Representatives”) of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “Offering”) of an aggregate of 13,333,333 shares o…

of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On October 31, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto. The Loan and Security Agreement provides a non-dilutive term loan facility (the “Loan Facility”) up to an aggregate principal amount of up to $150.0 million in multiple…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing. Forward-Looking Statements This Curre…

Director — Steve Liapis, Ph.D.: Dr. Liapis resigned from his position as a member of the Board and all committees thereof.

of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Chief Financial Officer — Marc Grasso: Dr. Marc Grasso was appointed as the Chief Financial Officer of Kyverna Therapeutics, Inc.

of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

or 7.01 of Form 8-K or to provide disclosure pursuant to

of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Chief Medical Officer — James Chung, M.D., Ph.D.: Dr. James Chung resigned from his role as Chief Medical Officer.

Chief Medical Officer — James Chung, M.D., Ph.D.: Dr. James Chung resigned from his position as Chief Medical Officer.

of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Class III director — Mert Aktar: Mr. Aktar was appointed as a Class III director and joined the Audit Committee and Science and Technology Committee.

Chief Executive Officer — Warner Biddle: Warner Biddle was appointed as the new Chief Executive Officer and a Class III director of Kyverna Therapeutics, Inc.